Citius Pharmaceuticals Files 8-K on Financials
Ticker: CTXR · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1506251
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Citius Pharma dropped an 8-K on Dec 27th covering financials. Check it out.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on December 27, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, incorporated in Nevada, is based in Cranford, NJ.
Why It Matters
This filing provides an update on Citius Pharmaceuticals' financial performance and condition, which is crucial information for investors and stakeholders to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate material events indicated.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- Cranford, NJ (location) — Principal executive offices
- December 27, 2024 (date) — Date of report
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filed?
The filing date, also the date of the earliest event reported, is December 27, 2024.
Where is Citius Pharmaceuticals, Inc. headquartered?
The company's principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
In which state is Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. is incorporated in Nevada.
What is the Commission File Number for Citius Pharmaceuticals, Inc.?
The Commission File Number for Citius Pharmaceuticals, Inc. is 001-38174.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-12-27 17:10:07
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0226161-8k_citius.htm (8-K) — 24KB
- ea022616101ex99-1_citius.htm (EX-99.1) — 86KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-24-113158.txt ( ) — 313KB
- ctxr-20241227.xsd (EX-101.SCH) — 3KB
- ctxr-20241227_lab.xml (EX-101.LAB) — 33KB
- ctxr-20241227_pre.xml (EX-101.PRE) — 22KB
- ea0226161-8k_citius_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On December 27, 2024, we issued a press release announcing our results of operations for the full year of fiscal 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated December 27, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: December 27, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2